Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TERIFLUNOMIDE SANDOZ, TERIFLUNOMIDE HX (Sandoz Pty Ltd)
Product name
TERIFLUNOMIDE SANDOZ, TERIFLUNOMIDE HX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
180 working days (255)
Active ingredients
teriflunomide
Registration type
New generic medicine
Indication
TERIFLUNOMIDE SANDOZ, TERIFLUNOMIDE HX (film coated tablets) are indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.